MAR 21, 2022 3:00 AM PDT

New Combination Therapy Effective in Hormone Sensitive Prostate Cancer

WRITTEN BY: Katie Kokolus

Like all cancers, prostate cancer has many classifications and subtypes. One such type is metastatic, hormone-sensitive prostate cancer (mHSPC).  Standard of care for patients with mHSPC includes androgen-deprivation therapy (ADT). Since prostate cancer growth is fueled by male sex hormones, collectively known as androgens, hindering their production or preventing them from reaching cancer cells can slow tumor progression. In addition to ADT, the treatment regimen for mHSPC patients includes either docetaxel, a taxane-based chemotherapy, or an androgen receptor antagonists, also referred to as anti-androgens or androgen receptor blockers, which block androgens from binding the cancer cell. A class of anti-androgen drugs is known as “next-generation” androgen receptor pathway inhibitors include FDA-approved drugs darlutamide, abiraterone, enzalutamide, apalutamide.    

Notably, recent phase 3 clinical trials have shown that several drugs can provide a survival benefit for mHSPC. The combination of ADT with chemotherapy docetaxel extends survival. Similarly, separate clinical trials have investigated the next-generation androgen receptor pathway inhibitors, and each (darolutamide, abiraterone, enzalutamide, apalutamide) improved the efficacy of ADT alone. 

Recently, a group of investigators explored whether a triple combination regimen of docetaxel, ADT, and an androgen receptor pathway inhibitor could provide added efficacy. Their findings were published in the New England Journal of Medicine. The study was named “Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer” (ARASENS; NCT02799602). ARASENS is an international, phase 3 trial in which mHSPC patients were randomized to receive ADT and docetaxel plus darolutamide (N=651) or ADT and docetaxel plus placebo (N=655).  

At the time of analysis, the study enrolled 1306 mHSPC patients (control group- N=655, darolutamide group- N=651).  The researchers found the risk of death 32.5% lower for patients in the darolutamide group than the placebo group.  Side effects were similar in the two groups indicating that the combination of three therapies did not increase the toxicity of the regimen. 

Overall, the large clinical trial, involving almost 300 international hospital sites, demonstrated that mHSPC patients benefit from adding darolutamide to standard treatment consisting of docetaxel and ADT.  This clinical combination appears to be a life-extending therapy that could significantly improve survivorship for mHSPC patients.  Additionally, exploring this combination in other subsets of prostate cancer could extend the use of its therapeutic potential. 

 

Sources: Oncol Ther, Drugs Aging, Annal Oncol, N Eng J Med, Lancet Oncol, N Eng J Med, J Clin Oncol, N Eng J Med

 

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
FEB 17, 2022
Cancer
Housing Insecurity Impedes Care of Cancer Survivors
FEB 17, 2022
Housing Insecurity Impedes Care of Cancer Survivors
A cancer diagnosis is something that no one wants.  We associate many burdens with cancer, such as enduring complex ...
FEB 21, 2022
Cancer
A Brief History of the US Presidents with Cancer
FEB 21, 2022
A Brief History of the US Presidents with Cancer
To date, 45 men have served as President of the United States (POTUS).  The National Cancer Institute estimates the ...
MAY 19, 2022
Cancer
Developing Methods to Predict Breast Cancer Recurrence
MAY 19, 2022
Developing Methods to Predict Breast Cancer Recurrence
Recurrent cancer develops when undetectable cancer cells remain in the body following treatment.  Cancer recurrence ...
JUN 16, 2022
Cancer
Dance/Movement Therapy Benefits Cancer Patients
JUN 16, 2022
Dance/Movement Therapy Benefits Cancer Patients
For cancer treatment, standard of care (sometimes referred to as best practice or standard therapy) defines medical trea ...
JUN 15, 2022
Drug Discovery & Development
High Intensity Ultrasound Therapy Treats Localized Prostate Cancer
JUN 15, 2022
High Intensity Ultrasound Therapy Treats Localized Prostate Cancer
High-intensity-focused ultrasound (HIFU) can treat some men with prostate cancer instead of surgery or radiation therapy ...
JUN 27, 2022
Technology
Machine Learning Predicts Which Genetic Mutations Drive Cancer Progression
JUN 27, 2022
Machine Learning Predicts Which Genetic Mutations Drive Cancer Progression
Understanding what drives cancer has perplexed scientists for years. However, what is abundantly clear is that mutations ...
Loading Comments...